Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. (Q51492835)

5 April 2018

title

Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. (English)

1 reference

5 April 2018

author name string

Luminita Ene

1

1 reference

5 April 2018

Tessa Goetghebuer

2

1 reference

5 April 2018

Marc Hainaut

3

1 reference

5 April 2018

Alexandra Peltier

4

1 reference

5 April 2018

Véronique Toppet

5

1 reference

5 April 2018

Jack Levy

6

1 reference

5 April 2018

publication date

29 July 2006

1 reference

5 April 2018

European Journal of Pediatrics

published in

1 reference

5 April 2018

volume

166

1 reference

5 April 2018

issue

1

1 reference

5 April 2018

page(s)

13-21

1 reference

5 April 2018

Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00431-006-0193-1

Agreement analysis of variables involved in lipodystrophy syndrome definition in HIV-infected patients

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00431-006-0193-1

Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00431-006-0193-1

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

21 January 2018

1 reference

12 December 2020

Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection

1 reference

12 December 2020

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

1 reference

12 December 2020

Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance.

1 reference

12 December 2020

Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children

1 reference

12 December 2020

Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children

1 reference

12 December 2020

An objective case definition of lipodystrophy in HIV-infected adults: a case-control study

1 reference

12 December 2020

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

1 reference

12 December 2020

Visceral abdominal-fat accumulation associated with use of indinavir

1 reference

12 December 2020

Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors.

1 reference

12 December 2020

Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine

1 reference

12 December 2020

Severe insulin resistance contrasting with mild anthropometric changes in the adipose tissue of HIV-infected children with lipohypertrophy

1 reference

12 December 2020

Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors

1 reference

12 December 2020

Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe

1 reference

12 December 2020

Adverse effects of antiretroviral therapy

1 reference

12 December 2020

Visceral adipose tissue and cardiovascular risk factors in obese children

1 reference

12 December 2020

Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment

1 reference

12 December 2020

Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection

1 reference

12 December 2020

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

12 December 2020

Validation and application of dual-energy x-ray absorptiometry to measure bone mass and body composition in small infants

1 reference

12 December 2020

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

1 reference

12 December 2020

Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens

1 reference

12 December 2020

Cardio- and cerebrovascular events in HIV-infected persons.

1 reference

12 December 2020

Metabolic complications of HIV therapy in children.

1 reference

12 December 2020

Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy

1 reference

12 December 2020

Hypertriglyceridemia in the acquired immunodeficiency syndrome

1 reference

12 December 2020

Lipodystrophy syndrome in human immunodeficiency virus-infected children

1 reference

12 December 2020

Antiretroviral-therapy-associated lipoatrophy: current status and future directions

1 reference

12 December 2020

Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy

1 reference

12 December 2020

Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection

1 reference

12 December 2020

Combination antiretroviral therapy and the risk of myocardial infarction

1 reference

12 December 2020

Pubertal alterations in growth and body composition. VI. Pubertal insulin resistance: relation to adiposity, body fat distribution and hormone release

1 reference

12 December 2020

Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals

1 reference

12 December 2020

Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy

1 reference

12 December 2020

Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy.

1 reference

12 December 2020

Visceral obesity, hypertriglyceridemia and hypercortisolism in a boy with perinatally acquired HIV infection receiving protease inhibitor-containing antiviral treatment

1 reference

12 December 2020

10.1007/S00431-006-0193-1

Identifiers

DOI

1 reference

5 April 2018

1 reference

5 April 2018